HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia

Figure 5

Evaluation of oncogene expression changes after NB4, HL60, and APL patient’s cell treatment with epigenetic agents in combination with conventional treatment. Cell samples were treated with 1 μM Retinoic acid (RA), 2 nM or 8 nM Idarubicin (IDA2 or IDA8), 0.5 μM 3-Deazaneplanocin A (D), and 0.2 μM Belinostat (B) in different combinations for 6 and 72 hours; C: untreated cells. Oncogene expression changes after treatment were measured using RT-qPCR ΔΔCt method. GAPDH was used as a “housekeeping” gene; results are presented as changes in comparison to untreated cells; results are mean ± S.D. (n = 3); P ≤ 0.05, calculated by one-way ANOVA statistical test.